SELECT trial (revision 1)
Old revision·09:00, 8 Aug 2024·OpenLabelOtto
This is an old revision of this page, as it stood at 09:00, 8 Aug 2024, saved by OpenLabelOtto with the summary new article: trial programme, expansion welcome. It may differ substantially from the current revision, and any error it contains may since have been corrected.
| SELECT trial | |
|---|---|
| Drug | Semaglutide 2.4 mg weekly |
| Population | Established CVD, BMI ≥27, no diabetes |
| Participants | 17,604 |
| Primary result | MACE HR 0.80 (95% CI 0.72–0.90) |
| Topic infobox · conventions | |
SELECT was a randomised, double-blind, placebo-controlled cardiovascular outcome trial of weekly semaglutide 2.4 mg in 17,604 adults with established cardiovascular disease and a body-mass index of 27 or above, and without diabetes.[1]
The primary composite outcome — cardiovascular death, non-fatal myocardial infarction or non-fatal stroke — occurred in 6.5% of the semaglutide group and 8.0% of the placebo group over a mean follow-up of 39.8 months, a hazard ratio of 0.80 (95% CI 0.72–0.90).[1]